DK1247097T3 - Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi - Google Patents

Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi

Info

Publication number
DK1247097T3
DK1247097T3 DK01902043T DK01902043T DK1247097T3 DK 1247097 T3 DK1247097 T3 DK 1247097T3 DK 01902043 T DK01902043 T DK 01902043T DK 01902043 T DK01902043 T DK 01902043T DK 1247097 T3 DK1247097 T3 DK 1247097T3
Authority
DK
Denmark
Prior art keywords
determining
cancer therapy
effectiveness
individual
response
Prior art date
Application number
DK01902043T
Other languages
Danish (da)
English (en)
Inventor
Sarah S Bacus
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of DK1247097T3 publication Critical patent/DK1247097T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/13—Tracers or tags

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
DK01902043T 2000-01-12 2001-01-12 Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi DK1247097T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17651400P 2000-01-12 2000-01-12
US17651500P 2000-01-12 2000-01-12
EP01902043A EP1247097B1 (fr) 2000-01-12 2001-01-12 Procede de determination de l'efficacite d'une therapie anticancereuse

Publications (1)

Publication Number Publication Date
DK1247097T3 true DK1247097T3 (da) 2004-11-29

Family

ID=26872320

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01902043T DK1247097T3 (da) 2000-01-12 2001-01-12 Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi

Country Status (10)

Country Link
US (2) US7833698B2 (fr)
EP (2) EP1247098A1 (fr)
JP (2) JP3699399B2 (fr)
AT (1) ATE271691T1 (fr)
AU (2) AU2951801A (fr)
CA (2) CA2397417A1 (fr)
DE (1) DE60104392T2 (fr)
DK (1) DK1247097T3 (fr)
MX (2) MXPA02006843A (fr)
WO (2) WO2001051924A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
AU5352901A (en) * 2000-04-14 2001-10-30 Ventana Med Syst Inc Method for quantification of akt protein expression
US20040085443A1 (en) * 2000-12-13 2004-05-06 Kallioniemi Olli P Method and system for processing regions of interest for objects comprising biological material
WO2003016867A2 (fr) 2001-08-21 2003-02-27 Ventana, Medical, Systems, Inc Methode et essai de quantification permettant d'evaluer l'etat du systeme c-kit/scf/pakt
GB0218909D0 (en) * 2002-08-15 2002-09-25 Qinetiq Ltd Histological assessment
US20030165263A1 (en) * 2002-02-19 2003-09-04 Hamer Michael J. Histological assessment
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
GB0229734D0 (en) * 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
EP1636585B2 (fr) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-urees presentant une activite d'inhibition des kinases
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
US7504225B2 (en) 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
US20070091109A1 (en) 2005-09-13 2007-04-26 Roscoe Atkinson Image quality
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
ZA200902233B (en) 2006-10-23 2010-07-28 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
DK2444807T3 (da) 2006-11-01 2014-08-11 Ventana Med Syst Inc Mono- og dinitropyrazolhaptenkonjugater
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
WO2010017822A1 (fr) 2008-08-15 2010-02-18 Visiopharm A/S Procédé et système de détermination d'une cible dans un échantillon biologique par analyse d'image
AU2008216748A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
WO2008108059A1 (fr) * 2007-03-01 2008-09-12 Nec Corporation Système, procédé et programme pour le diagnostic d'images pathologiques de cancer mammaire, et support d'enregistrement du programme
EP2167963B1 (fr) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Supports polymères pour immunohistochimie et hybridation in situ
KR101667960B1 (ko) * 2007-07-25 2016-10-20 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
EP2453234B1 (fr) * 2007-10-29 2014-01-15 Eisai R&D Management Co., Ltd. Procédés pour le pronostic de la capacité d'un composé à base d'un analogue de la zéaralénone à traiter le cancer
WO2009149013A2 (fr) 2008-06-05 2009-12-10 Ventana Medical Systems, Inc. Compositions comprenant des nanomatériaux et procédé d'utilisation de ces compositions pour des processus histochimiques
CA2734446C (fr) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methodes et compositions pour le traitement de deficits osseux au moyen de populations de cellules placentaires
GB2464747B (en) * 2008-10-10 2013-05-15 Hai Kang Life Corp Ltd Method for detection of analyte in microarray of samples and apparatus for performing such method
EP2387711B1 (fr) * 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Procédés permettant de déterminer la réponse d'un patient par mesure de her-3
WO2010099923A1 (fr) 2009-03-04 2010-09-10 Roche Diagnostics Gmbh Serpine b 13 en tant que marqueur du carcinome épidermoïde du poumon
WO2010141543A1 (fr) * 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Procédés de détection et de détermination quantitative de la composante p95 de her2/neu (erbb2)
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
JP5490568B2 (ja) * 2010-02-26 2014-05-14 オリンパス株式会社 顕微鏡システム、標本観察方法およびプログラム
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
US8524239B2 (en) * 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9092850B2 (en) * 2011-01-21 2015-07-28 Carnegie Mellon University Identifying location biomarkers
JP6104896B2 (ja) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション 胎盤幹細胞を使用する疼痛の治療
US20130338014A1 (en) * 2012-04-05 2013-12-19 Vala Sciences, Inc. Calibration Standards For Digital Histocytometry
EP2864794A4 (fr) * 2012-06-20 2016-03-02 Merrimack Pharmaceuticals Inc Quantification de marqueur dans des cellules isolées dans des sections de tissu
US10830678B2 (en) 2014-08-08 2020-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Photo-controlled removal of targets in vitro and in vivo
US10304188B1 (en) 2015-03-27 2019-05-28 Caleb J. Kumar Apparatus and method for automated cell analysis
CN121270700A (zh) 2015-08-07 2026-01-06 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
US11154620B2 (en) 2015-08-18 2021-10-26 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
ES2889904T3 (es) 2015-08-18 2022-01-14 Rakuten Medical Inc Conjugados de colorante de ftalocianina y su almacenamiento
US10846852B2 (en) * 2016-12-23 2020-11-24 Bio-Rad Laboratories, Inc. Reduction of background signal in blot images
JPWO2018207361A1 (ja) * 2017-05-12 2020-03-12 オリンパス株式会社 細胞画像取得装置
SG11202011538RA (en) 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
WO2020232133A1 (fr) * 2019-05-14 2020-11-19 Georgetown University Procédés de traitement de cancers gastro-intestinaux et de leurs tumeurs faisant intervenir une polythérapie
CN118609852B (zh) * 2024-06-09 2024-11-22 中南大学 基于可解释模型预测感染性休克者亚甲蓝治疗响应的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741043B1 (en) * 1985-11-04 1994-08-09 Cell Analysis Systems Inc Method of and apparatus for image analyses of biological specimens
US5086476A (en) 1985-11-04 1992-02-04 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US5008185A (en) 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
US5109429A (en) 1985-11-04 1992-04-28 Cell Analysis Systems,Inc. Apparatus and method for analyses of biological specimens
US5202931A (en) * 1987-10-06 1993-04-13 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear protein
US5389523A (en) * 1988-05-31 1995-02-14 The United States Of Americas, As Represented By The Secretary Of Commerce Liposome immunoanalysis by flow injection assay
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0378383A3 (fr) * 1989-01-10 1991-09-11 ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA Méthode et dispositif pour détection, validation et quantification d'antigènes associés à des résistances multiples aux drogues
US5784162A (en) * 1993-08-18 1998-07-21 Applied Spectral Imaging Ltd. Spectral bio-imaging methods for biological research, medical diagnostics and therapy
DE69228300T2 (de) * 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
EP1134293A3 (fr) * 1992-03-04 2004-01-07 The Regents of The University of California Hybridation génomique comparative
CA2094341A1 (fr) * 1992-04-28 1993-10-29 Carl W. Porter Methodes d'utilisation de la n1-acetyltransferase spermidine/spermine comme indicateur pronostique et/ou marqueur de la reponse tumorale
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
US5491069A (en) * 1994-02-18 1996-02-13 The Regents Of The University Of California Biomarkers of cell senescence
US6463438B1 (en) * 1994-06-03 2002-10-08 Urocor, Inc. Neural network for cell image analysis for identification of abnormal cells
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5998151A (en) 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
US6165734A (en) 1995-12-12 2000-12-26 Applied Spectral Imaging Ltd. In-situ method of analyzing cells
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5935801A (en) * 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
US6447997B1 (en) * 1997-07-18 2002-09-10 Research Development Foundation Gene coding for GADD153 as a clinical diagnostic and prognostic in cancer therapy
WO1999016789A1 (fr) * 1997-09-30 1999-04-08 Peviva Ab Composes associes a l'apoptose et leur utilisation
AU734226B2 (en) * 1997-11-10 2001-06-07 Regents Of The University Of California, The Biochemical methods for detecting cervical dysplasia and cancer
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6350452B1 (en) * 1998-09-24 2002-02-26 Promega Corporation Apoptosis marker antibodies and methods of use
AU770729B2 (en) * 1998-10-21 2004-02-26 Steven Jay Smith Protein quantitation with cell imaging densitometry
US6372895B1 (en) * 2000-07-07 2002-04-16 3M Innovative Properties Company Fluorogenic compounds
CA2432976A1 (fr) * 2000-12-21 2002-08-08 Board Of Trustees Of The University Of Illinois Reactifs et procedes d'identification et de modulation de l'expression de genes de senescence tumorale

Also Published As

Publication number Publication date
DE60104392D1 (de) 2004-08-26
CA2397417A1 (fr) 2001-07-19
MXPA02006778A (es) 2004-04-05
CA2397772A1 (fr) 2001-07-19
WO2001051928A9 (fr) 2002-10-24
US6962789B2 (en) 2005-11-08
EP1247098A1 (fr) 2002-10-09
CA2397772C (fr) 2007-06-12
WO2001051928A1 (fr) 2001-07-19
WO2001051924A2 (fr) 2001-07-19
AU785347B2 (en) 2007-02-01
ATE271691T1 (de) 2004-08-15
US20010044124A1 (en) 2001-11-22
US7833698B2 (en) 2010-11-16
EP1247097B1 (fr) 2004-07-21
WO2001051924A3 (fr) 2002-01-10
DE60104392T2 (de) 2005-08-11
MXPA02006843A (es) 2004-04-05
JP3699399B2 (ja) 2005-09-28
US20010049114A1 (en) 2001-12-06
AU2788701A (en) 2001-07-24
JP2003519795A (ja) 2003-06-24
AU2951801A (en) 2001-07-24
JP2003519796A (ja) 2003-06-24
EP1247097A2 (fr) 2002-10-09

Similar Documents

Publication Publication Date Title
DK1247097T3 (da) Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi
DK0960558T3 (da) Fremgangsmåder til frembringelse af udbyttekort
DE60322453D1 (de) System zum Bereitstellen von Diensten
NO20024562D0 (no) Seismiske kildegrupper
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
PT103029B (pt) Inibidores de dopamina-beta-hidroxilase selectivos perifericamente e metodo paraa sua preparacao
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DK1193010T3 (da) Vendeplatte til drejning
DE60132459D1 (de) Pupillenmesssystem
DE60212776D1 (de) Spezifisches Bindungsanalyseverfahren
NO20030937D0 (no) Kreatin-ester pronutrient forbindelser og utforminger
DE60115144D1 (de) Verkettung über unabhängige Zeiger-Prozessoren
DK1385993T3 (da) Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser
NO20030751D0 (no) Sensor for seismisk kilde
DE60131665D1 (de) Vorrichtung zur mikrostromtherapie
AT500412B1 (de) Flüssigmetall-ionenquelle
ATE343390T1 (de) Kalzilytische verbindungen
DE50110746D1 (de) Wiederablösbare Vorrichtung
DE60207833D1 (de) Peptiddeformylase-hemmer
DK1372607T5 (da) Adjuvans-emulsion og fremgangsmåde til anvendelse af nævnte emulsion
DE60229515D1 (de) Ionenstrahl vorrichtung
IS7441A (is) Peptíðdeformýlasatálmar
ITBO20000398A0 (it) Tozzetto e metodo per la sua realizzazione .
DE60232650D1 (de) Peptiddeformylaseinhibitoren
DE60305102D1 (de) Vorrichtung zur Auswahl von bimetallischen Münzen